+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors

HIV Medicine 5(1): 11-14

Most toxicities associated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) are thought to result from mitochondrial toxicity. These toxicities include peripheral neuropathy, pancreatitis, lactic acidosis, and peripheral lipoatrophy. Unfortunately, there are no validated laboratory markers for clinically assessing, let alone predicting, the onset of mitochondrial toxicity associated with NRTI therapy. To provide preliminary evidence of the potential clinical utility of an assay which has been developed for quantifying mitochondrial DNA (mtDNA) in clinical samples from HIV-infected patients. A single-tube duplex real-time DNA-nucleic acid sequence-based amplification (NASBA) assay (Mitox, Primagen, Amsterdam, the Netherlands) was used to quantify mtDNA in cryopreserved peripheral blood mononuclear cells (PBMC) obtained from HIV-1-infected patients during their prior participation in a randomized placebo-controlled trial comparing zidovudine (ZDV) monotherapy with combinations of ZDV plus either dideoxycytidine (ddC) or didanosine (ddI) (the Delta trial). Patients were antiretroviral naïve prior to entering the trial. Samples obtained during the initial 48 weeks of treatment were tested. A significant decline of mtDNA, both in an intent-to-treat and in an as-treated analysis, was observed in patients treated with ZDV+ddC and ZDV+ddI, but not with ZDV alone, consistent with the results expected from the degree of mtDNA depletion described for each of these drugs in vitro. This single-tube duplex real-time DNA-NASBA assay was shown to measure mtDNA accurately in PBMC. Treatment with a combination of two NRTIs was associated with greater reductions in mtDNA than obtained for ZDV monotherapy. The relevance of these results in predicting treatment toxicity requires further evaluation.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 049171833

Download citation: RISBibTeXText

PMID: 14731163

DOI: 10.1111/j.1468-1293.2004.00178.x

Related references

Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors. Journal of Medical Virology 68(1): 1-6, 2002

Retrospective study of zidovudine or didanosine monotherapy or zalcitabine plus zidovudine combination therapy in patients with early AIDS. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD [Author] Tenth International Conference on AIDS and the International Conference on STD, Vol 1; The global challenge of AIDS: Together for the future : 1) 209, 1994

Development of Lys to Arg mutation at codon 70 of the reverse transcriptase gene of HIV-1 during zidovudine monotherapy and alternating zidovudine/didanosine therapy. Antiviral Therapy 3(2): 89-95, 1998

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Aids Research and Human Retroviruses 16(14): 1337-1344, 2000

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 173(6): 1354-1366, 1996

The nucleoside reverse transcriptase inhibitors didanosine, lamivudine, stavudine and zidovudine show little effect on the virulence of Candida albicans in vitro. International Journal of Antimicrobial Agents 32(2): 186-191, 2008

Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet (North American Edition) 348(9023): 283-291, 1996

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 13(7): 851-858, 1999

Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 50(4): 335-339, 1998

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. Pediatric Infectious Disease Journal 24(6): 503-509, 2005

A six months follow-up randomized controlled trial of lamivudine combined with zidovudine vs lamivudine plus zidovudine plus zalcitabine or didanosine in HIV-1 infection and CD4+ cell count between 50-300/mu-L. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 206, 1996

Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. Journal of Chromatography. B Analytical Technologies in the Biomedical and Life Sciences 816(1-2): 121-129, 2005